Published in J Alzheimers Dis on January 01, 2012
Synergistic effects of hypertension and aging on cognitive function and hippocampal expression of genes involved in β-amyloid generation and Alzheimer's disease. Am J Physiol Heart Circ Physiol (2013) 0.92
Hypertension and Its Role in Cognitive Function: Current Evidence and Challenges for the Future. Am J Hypertens (2015) 0.86
Roles of Brain Angiotensin II in Cognitive Function and Dementia. Int J Hypertens (2012) 0.84
Angiotensin converting enzyme inhibitors and the reduced risk of Alzheimer's disease in the absence of apolipoprotein E4 allele. J Alzheimers Dis (2013) 0.83
A Meta-Analysis of Alzheimer's Disease Incidence and Prevalence Comparing African-Americans and Caucasians. J Alzheimers Dis (2015) 0.82
Modulation of Renin-Angiotensin System May Slow Conversion from Mild Cognitive Impairment to Alzheimer's Disease. J Am Geriatr Soc (2015) 0.82
Morphometry of the hippocampal microvasculature in post-stroke and age-related dementias. Neuropathol Appl Neurobiol (2014) 0.81
The association of angiotensin-converting enzyme with biomarkers for Alzheimer's disease. Alzheimers Res Ther (2014) 0.81
Telmisartan Modulates Glial Activation: In Vitro and In Vivo Studies. PLoS One (2016) 0.76
An inventory for measuring depression. Arch Gen Psychiatry (1961) 84.61
Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol (2002) 16.25
Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ (2010) 3.98
Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol (1999) 3.62
The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med (2002) 3.61
Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s. J Am Coll Cardiol (2008) 3.36
Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol (1995) 3.23
Mental rotations, a group test of three-dimensional spatial visualization. Percept Mot Skills (1978) 3.03
Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med (2003) 3.02
Effects of blood pressure lowering on cerebral white matter hyperintensities in patients with stroke: the PROGRESS (Perindopril Protection Against Recurrent Stroke Study) Magnetic Resonance Imaging Substudy. Circulation (2005) 2.97
An analysis of the relationship between central aortic and peripheral upper limb pressure waves in man. Eur Heart J (1993) 2.84
Angiotensin-converting enzyme inhibitors and cognitive decline in older adults with hypertension: results from the Cardiovascular Health Study. Arch Intern Med (2009) 2.82
Antihypertensive medication use and incident Alzheimer disease: the Cache County Study. Arch Neurol (2006) 2.71
Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med (2007) 2.69
Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett (2000) 2.25
Relationship of vascular risk to the progression of Alzheimer disease. Neurology (2006) 2.08
Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. Clin Chem (2001) 1.87
Determination of pulse wave velocities with computerized algorithms. Am Heart J (1991) 1.85
A link between sICAM-1, ACE and parietal blood flow in the aging brain. Neurobiol Aging (2008) 1.69
Regulation of steady-state beta-amyloid levels in the brain by neprilysin and endothelin-converting enzyme but not angiotensin-converting enzyme. J Biol Chem (2006) 1.42
Aβ-degrading enzymes: potential for treatment of Alzheimer disease. J Neuropathol Exp Neurol (2011) 1.42
Effects of brain-penetrating ACE inhibitors on Alzheimer disease progression. Neurology (2004) 1.36
Antihypertensive drugs and incidence of dementia: the Rotterdam Study. Neurobiol Aging (2001) 1.34
Angiotensins in Alzheimer's disease - friend or foe? Trends Neurosci (2009) 1.25
Beta-amyloid deposition in brain is enhanced in mouse models of arterial hypertension. Neurobiol Aging (2007) 1.23
Parietal cortex matters in Alzheimer's disease: an overview of structural, functional and metabolic findings. Neurosci Biobehav Rev (2011) 1.23
A neuropsychological battery for epilepsy. Epilepsia (1978) 1.21
Cortical alterations of angiotensin converting enzyme, angiotensin II and AT1 receptor in Alzheimer's dementia. Neurobiol Aging (2001) 1.19
Angiotensin-converting enzyme levels and activity in Alzheimer's disease: differences in brain and CSF ACE and association with ACE1 genotypes. Am J Transl Res (2009) 1.15
Cross-sectional and longitudinal association between antihypertensive medications and cognitive impairment in an elderly population. J Gerontol A Biol Sci Med Sci (2005) 1.13
Associations of anti-hypertensive treatments with Alzheimer's disease, vascular dementia, and other dementias. J Alzheimers Dis (2011) 1.13
Blood-brain barrier permeability in Alzheimer's disease: a case-control MRI study. Psychiatry Res (2009) 1.10
Angiotensin II inhibits the release of [3H]acetylcholine from rat entorhinal cortex in vitro. Brain Res (1989) 1.08
Central angiotensin II stimulation promotes β amyloid production in Sprague Dawley rats. PLoS One (2011) 1.08
Angiotensin converting enzyme (ACE) inhibitors modulate the rate of progression of amnestic mild cognitive impairment. Int J Geriatr Psychiatry (2006) 1.07
Angiotensin-converting enzyme inhibitors and incidence of Alzheimer's disease in Japan. J Am Geriatr Soc (2004) 1.06
The renin-angiotensin system and antihypertensive drugs in Alzheimer's disease: current standing of the angiotensin hypothesis? J Alzheimers Dis (2012) 1.05
Cognitive and neuroendocrine response to transdermal estrogen in postmenopausal women with Alzheimer's disease: results of a placebo-controlled, double-blind, pilot study. Psychoneuroendocrinology (1999) 1.02
Involvement of angiotensin converting enzyme in cerebral hypoperfusion induced anterograde memory impairment and cholinergic dysfunction in rats. Neuroscience (2008) 1.01
Angiotensin converting enzyme density is increased in temporal cortex from patients with Alzheimer's disease. Eur J Pharmacol (1991) 0.96
Age-related decline in spatial learning and memory: attenuation by captopril. Clin Exp Hypertens (2003) 0.94
The role of the brain renin-angiotensin system in neurodegenerative disorders. Curr Alzheimer Res (2005) 0.91
A multi-center study of ACE and the risk of late-onset Alzheimer's disease. J Alzheimers Dis (2011) 0.89
Effect of enalapril maleate on cerebral blood flow in patients with chronic heart failure. Angiology (1997) 0.85
Angiotensin II-inhibiting drugs have no effect on intraneuronal Aβ or oligomeric Aβ levels in a triple transgenic mouse model of Alzheimer's disease. Am J Transl Res (2011) 0.81
Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol (2006) 9.99
Caloric restriction delays disease onset and mortality in rhesus monkeys. Science (2009) 9.84
Alzheimer's disease. Lancet (2006) 9.15
CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA (2009) 7.29
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol (2010) 6.55
Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol (2010) 5.53
American Society of Echocardiography recommendations for use of echocardiography in clinical trials. J Am Soc Echocardiogr (2004) 4.88
Developing a national strategy to prevent dementia: Leon Thal Symposium 2009. Alzheimers Dement (2010) 4.85
Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov (2010) 4.55
Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. Alzheimers Dement (2007) 3.75
Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care (2008) 3.65
Predictive markers for AD in a multi-modality framework: an analysis of MCI progression in the ADNI population. Neuroimage (2010) 3.58
Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s. J Am Coll Cardiol (2008) 3.36
Blood biomarkers for brain injury in concussed professional ice hockey players. JAMA Neurol (2014) 3.29
A generalized form of context-dependent psychophysiological interactions (gPPI): a comparison to standard approaches. Neuroimage (2012) 3.28
Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol (2008) 3.15
Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol (2008) 3.03
The role of biomarkers in clinical trials for Alzheimer disease. Alzheimer Dis Assoc Disord (2006) 2.86
Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE). Circulation (2007) 2.82
Outcomes in 45 patients with statin-associated myopathy. Arch Intern Med (2005) 2.80
Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization. J Neurosci (2008) 2.77
Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry (2012) 2.68
ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol (2008) 2.67
Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Arch Neurol (2012) 2.61
Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neurobiol Aging (2008) 2.51
Spatially augmented LPboosting for AD classification with evaluations on the ADNI dataset. Neuroimage (2009) 2.47
Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch Neurol (2012) 2.39
Cerebrospinal fluid beta-amyloid 1-42 concentration may predict cognitive decline in older women. J Neurol Neurosurg Psychiatry (2006) 2.39
The influence of Alzheimer disease family history and apolipoprotein E epsilon4 on mesial temporal lobe activation. J Neurosci (2006) 2.34
Does detection of carotid plaque affect physician behavior or motivate patients? Am Heart J (2007) 2.33
Prospective study of particulate air pollution exposures, subclinical atherosclerosis, and clinical cardiovascular disease: The Multi-Ethnic Study of Atherosclerosis and Air Pollution (MESA Air). Am J Epidemiol (2012) 2.23
Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry (2005) 2.21
State of the science conference: Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary. Circulation (2008) 2.17
Metacognitive evaluation, self-relevance, and the right prefrontal cortex. Neuroimage (2004) 2.17
The neuropathology and neurobiology of traumatic brain injury. Neuron (2012) 1.99
Longitudinal changes in patients with traumatic brain injury assessed with diffusion-tensor and volumetric imaging. Neuroimage (2008) 1.97
A population-average MRI-based atlas collection of the rhesus macaque. Neuroimage (2008) 1.94
CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimers Dement (2013) 1.90
Relevance to self: A brief review and framework of neural systems underlying appraisal. Neurosci Biobehav Rev (2007) 1.87
The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement (2011) 1.87
Confounding factors influencing amyloid Beta concentration in cerebrospinal fluid. Int J Alzheimers Dis (2010) 1.86
Reliability and precision of pseudo-continuous arterial spin labeling perfusion MRI on 3.0 T and comparison with 15O-water PET in elderly subjects at risk for Alzheimer's disease. NMR Biomed (2010) 1.85
Proteomic analysis using protein chips to detect biomarkers in cervical and amniotic fluid in women with intra-amniotic inflammation. J Proteome Res (2005) 1.84
Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment. Dement Geriatr Cogn Disord (2007) 1.76
Total and phosphorylated tau protein as biological markers of Alzheimer's disease. Exp Gerontol (2009) 1.75
The effect of body mass index on global brain volume in middle-aged adults: a cross sectional study. BMC Neurol (2005) 1.74
Relationship of cognitive measures and gray and white matter in Alzheimer's disease. J Alzheimers Dis (2006) 1.74
Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington's disease patients. J Clin Invest (2015) 1.74
Anteroposterior somatotopy of innocuous cooling activation focus in human dorsal posterior insular cortex. Am J Physiol Regul Integr Comp Physiol (2005) 1.68
Cerebrospinal fluid amyloid-β and phenotypic heterogeneity in de novo Parkinson's disease. J Neurol Neurosurg Psychiatry (2012) 1.66
Effects of smoking and smoking cessation on endothelial function: 1-year outcomes from a randomized clinical trial. J Am Coll Cardiol (2010) 1.61
Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss? Neurosci Lett (2008) 1.60
Interaction of apolipoprotein E genotype with smoking and physical inactivity on coronary heart disease risk in men and women. Atherosclerosis (2011) 1.58
PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses. J Alzheimers Dis (2010) 1.57
Apolipoprotein E polymorphisms in patients with primary open-angle glaucoma. Am J Ophthalmol (2007) 1.56
CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study. J Neurol Neurosurg Psychiatry (2010) 1.55
Longitudinal stability of CSF biomarkers in Alzheimer's disease. Neurosci Lett (2007) 1.54
Cerebrospinal fluid markers of brain injury, inflammation, and blood-brain barrier dysfunction in cardiac surgery. Ann Thorac Surg (2012) 1.53
Development and assessment of sensitive immuno-PCR assays for the quantification of cerebrospinal fluid three- and four-repeat tau isoforms in tauopathies. J Neurochem (2012) 1.52
A novel pathway for amyloid precursor protein processing. Neurobiol Aging (2009) 1.52
Characterization of amyloid beta peptides in cerebrospinal fluid by an automated immunoprecipitation procedure followed by mass spectrometry. J Proteome Res (2007) 1.51
Increased subclinical atherosclerosis in young adults with metabolic syndrome: the Bogalusa Heart Study. J Am Coll Cardiol (2005) 1.50
Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease. Ann Neurol (2008) 1.50
CSF amyloid β38 as a novel diagnostic marker for dementia with Lewy bodies. J Neurol Neurosurg Psychiatry (2010) 1.50
Effects of smoking and smoking cessation on lipids and lipoproteins: outcomes from a randomized clinical trial. Am Heart J (2011) 1.50
Latent structure and factorial invariance of a neuropsychological test battery for the study of preclinical Alzheimer's disease. Neuropsychology (2010) 1.49
The influence of parental history of Alzheimer's disease and apolipoprotein E epsilon4 on the BOLD signal during recognition memory. Brain (2008) 1.47
Biological markers of amyloid beta-related mechanisms in Alzheimer's disease. Exp Neurol (2009) 1.47
Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer's disease. Acta Neuropathol (2010) 1.46
White matter is altered with parental family history of Alzheimer's disease. Alzheimers Dement (2010) 1.45
Cardiovascular risks of antiretroviral therapy. N Engl J Med (2007) 1.45
Fluid biomarkers in Alzheimer's disease - current concepts. Mol Neurodegener (2013) 1.44
Advanced lipoprotein testing does not improve identification of subclinical atherosclerosis in young adults: the Bogalusa Heart Study. Ann Intern Med (2005) 1.44
Insulin dose-response effects on memory and plasma amyloid precursor protein in Alzheimer's disease: interactions with apolipoprotein E genotype. Psychoneuroendocrinology (2003) 1.44
A prospective randomized controlled trial of the effects of vitamin D supplementation on cardiovascular disease risk. PLoS One (2012) 1.44
Antihypertensive therapy is associated with reduced rate of conversion to Alzheimer's disease in midregional proatrial natriuretic peptide stratified subjects with mild cognitive impairment. Biol Psychiatry (2011) 1.43
Lower CSF amyloid beta peptides and higher F2-isoprostanes in cognitively intact elderly individuals with major depressive disorder. Am J Psychiatry (2012) 1.43
Cerebrospinal fluid and neuroimaging biomarker abnormalities suggest early neurological injury in a subset of individuals during primary HIV infection. J Infect Dis (2013) 1.42
Self-appraisal decisions evoke dissociated dorsal-ventral aMPFC networks. Neuroimage (2005) 1.42
Reduced hippocampal activation during episodic encoding in middle-aged individuals at genetic risk of Alzheimer's disease: a cross-sectional study. BMC Med (2006) 1.42
Topology-based kernels with application to inference problems in Alzheimer's disease. IEEE Trans Med Imaging (2011) 1.41